Dulera Inhalation Aerosol, which is used to treat asthma combines mometasone furoate, an inhaled corticosteroid, and formoterol fumarate, a long-acting beta2-agonist.
The two 26-week, multicenter, double-blind, placebo controlled trials comprising 2,251 with moderate to very severe COPD were randomized to receive inhaled Dulera 400 mcg/10 mcg, Dulera 200 mcg/10mcg, mometasone furoate 400 mcg, formoterol 10 mcg or placebo, each administered twice daily.
In the two studies, Dulera showed improved lung function as compared to treatment with mometasone furoate.